{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:16:44Z","timestamp":1773386204003,"version":"3.50.1"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Onychomycosis is a common, difficult to treat nail disorder. Our objective was to explore disparities in current clinical management practices for onychomycosis in patients from underrepresented groups and with specific comorbidities. We conducted a cross-sectional study using the All of Us (AoU) research program. The AoU program gathers survey, and electronic health records from participants in the United States with the aim of increasing the representation of minorities groups in health research under the framework of precision medicine. We identified 18,763 onychomycosis patients (2017\u20132022) and compared the rates of diagnostic testing, prescription medications and surgical procedures. Younger patients were more likely to receive oral medications, while older patients were more likely to undergo surgical nail procedures. Patients with lower income and education, Black and Hispanic patients were less likely to receive testing to confirm diagnosis, and less likely to receive prescription medications (topical and\/or oral) except in the case of fluconazole. Lower income and education were associated with a higher likelihood of debridement and trimming procedures, while Black and Hispanic patients were less likely to undergo these procedures. Patients with disabilities also received different treatments when compared to able-bodied individuals, being less likely to receive ciclopirox, efinaconazole and terbinafine, but more likely to undergo debridement and trimming procedures. There are clear differences in the management of onychomycosis in the different demographic and comorbid populations that we studied. Efforts to reduce these inequalities, such as expanded health coverage, reducing communication barriers and increasing patient and physician education are needed.<\/jats:p>","DOI":"10.1371\/journal.pone.0316681","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T18:23:48Z","timestamp":1736879028000},"page":"e0316681","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Epidemiological trends and healthcare disparities in onychomycosis: An analysis of the All of Us research program"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":true,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasiliki","family":"Economopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"1","key":"pone.0316681.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.mm7301a1","article-title":"Topical Antifungal Prescribing for Medicare Part D Beneficiaries\u2014United States, 2021","volume":"73","author":"K Benedict","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"pone.0316681.ref002","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/jdv.13677","article-title":"The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians\u2019 offices","volume":"30","author":"AK Gupta","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2 I","key":"pone.0316681.ref003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1067\/mjd.2000.104794","article-title":"Prevalence and epidemiology of onychomycosis in patients visiting physicians\u2019 offices: A multicenter Canadian survey of 15,000 patients","volume":"43","author":"AK Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"1492","key":"pone.0316681.ref004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2133.1992.tb00005.x","article-title":"Prevalence of dermatophyte onychomycosis in the United Kingdom: Results of an omnibus survey","volume":"126","author":"DT Roberts","year":"1992","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"pone.0316681.ref005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004105","article-title":"Fungal Nail Infections (Onychomycosis): A Never-Ending Story?","volume":"10","author":"M Ghannoum","year":"2014","journal-title":"PLoS Pathog"},{"issue":"5","key":"pone.0316681.ref006","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jaad.2022.02.046","article-title":"Geriatric dermatology: Grow old along with me!","volume":"86","author":"WR Heymann","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"pone.0316681.ref007","first-page":"1","article-title":"Evaluation of relationships between onychomycosis and vascular diseases using sequential pattern mining","volume":"8","author":"CH Bang","year":"2018","journal-title":"Sci Rep"},{"issue":"8","key":"pone.0316681.ref008","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/jof10080577","article-title":"Diabetic Foot and Fungal Infections: Etiology and Management from a Dermatologic Perspective","volume":"10","author":"AK Gupta","year":"2024","journal-title":"Journal of Fungi"},{"issue":"4","key":"pone.0316681.ref009","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2133.1998.02464.x","article-title":"Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: A multicentre survey","volume":"139","author":"AK Gupta","year":"1998","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"pone.0316681.ref010","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaad.2021.12.061","article-title":"Racial\/ethnic health disparities in dermatology in the United States, part 1: Overview of contributing factors and management strategies","volume":"87","author":"J Hooper","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"pone.0316681.ref011","first-page":"1","volume-title":"2023 National Healthcare Quality and Disparities Report","author":"Agency for Healthcare Research and Quality","year":"2023"},{"issue":"5","key":"pone.0316681.ref012","first-page":"1215","article-title":"Racial disparities in dermatology","volume":"315","author":"S Narla","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"pone.0316681.ref013","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/DSS.0000000000000909","article-title":"Dermatologic surgery needs in low-income, uninsured, and minority communities","volume":"43","author":"AA Jacobsen","year":"2017","journal-title":"Dermatologic Surgery"},{"issue":"7","key":"pone.0316681.ref014","doi-asserted-by":"crossref","DOI":"10.3390\/jof9070712","article-title":"Risk Factors and Treatment Trends for Onychomycosis: A Case\u2014Control Study of Onychomycosis Patients in the All of Us Research Program","volume":"9","author":"SJ Albucker","year":"2023","journal-title":"Journal of Fungi"},{"issue":"3","key":"pone.0316681.ref015","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00403-022-02413-4","article-title":"Onychomycosis in underrepresented groups: an all of us database analysis","volume":"315","author":"I Moseley","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"pone.0316681.ref016","doi-asserted-by":"crossref","DOI":"10.1016\/j.patter.2022.100570","article-title":"The All of Us Research Program: Data quality, utility, and diversity","volume":"3","author":"AH Ramirez","year":"2022","journal-title":"Patterns"},{"key":"pone.0316681.ref017","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-biodatasci-122120-104825","article-title":"The All of Us Data and Research Center: Creating a Secure, Scalable, and Sustainable Ecosystem for Biomedical Research","volume":"6","author":"KR Mayo","year":"2023","journal-title":"Annu Rev Biomed Data Sci"},{"issue":"7","key":"pone.0316681.ref018","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMsr1809937","article-title":"The \u201cAll of Us\u201d Research Program","volume":"381","author":"JC Denny","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"pone.0316681.ref019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.det.2008.12.001","article-title":"Health Care Inequities: An Introduction for Dermatology Providers","volume":"27","author":"A Sauaia","year":"2009","journal-title":"Dermatol Clin"},{"issue":"1","key":"pone.0316681.ref020","first-page":"3","article-title":"Global health dermatology: An emerging field addressing the access to care crisis","volume":"90","author":"EE Freeman","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"pone.0316681.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/myc.13725","article-title":"Global prevalence of onychomycosis in general and special populations: An updated perspective","volume":"67","author":"AK Gupta","year":"2024","journal-title":"Mycoses"},{"issue":"5","key":"pone.0316681.ref022","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2133.1997.tb03673.x","article-title":"A higher prevalence of onychomycosis in psoriatics compared with non- psoriatics: A multicentre study","volume":"136","author":"AK Gupta","year":"1997","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"pone.0316681.ref023","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2710.2009.01107.x","article-title":"Toenail onychomycosis: an important global disease burden","volume":"35","author":"J Thomas","year":"2010","journal-title":"J Clin Pharm Ther"},{"issue":"202","key":"pone.0316681.ref024","first-page":"1","article-title":"Prognostic Factors in Onychomycosis Treatment","volume":"03","author":"SR Lipner","year":"2015","journal-title":"Journal of Infectious Diseases and Therapy"},{"issue":"6","key":"pone.0316681.ref025","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1046\/j.1468-3083.2000.00124.x","article-title":"The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease","volume":"14","author":"AK Gupta","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"pone.0316681.ref026","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.12239","article-title":"The prevalence of onychomycosis in psoriatic patients: a systematic review","volume":"28","author":"KMG Klaassen","year":"2014","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"pone.0316681.ref027","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1067\/mjd.2000.110376","article-title":"Onychomycosis and tinea pedis in patients with diabetes","volume":"43","author":"P Rich","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"pone.0316681.ref028","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00128071-200910040-00001","article-title":"Toenail onychomycosis in diabetic patients: Issues and management","volume":"10","author":"P Mayser","year":"2009","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"pone.0316681.ref029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2023-076441","article-title":"Association between onychomycosis and ulcerative complications in patients with diabetes: a longitudinal cohort study in Dutch general practice","volume":"14","author":"RM Watjer","year":"2024","journal-title":"BMJ Open"},{"issue":"2","key":"pone.0316681.ref030","doi-asserted-by":"crossref","DOI":"10.3390\/jof10020149","article-title":"Clinical Diagnosis and Laboratory Testing of Abnormal Appearing Toenails: A Retrospective Assessment of Confirmatory Testing for Onychomycosis in the United States, 2022\u20132023","volume":"10","author":"AK Gupta","year":"2024","journal-title":"Journal of Fungi"},{"issue":"3","key":"pone.0316681.ref031","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jaad.2022.06.1201","article-title":"Opportunities to improve guideline adherence for the diagnosis and treatment of onychomycosis: Analysis of commercial insurance claims data, United States","volume":"88","author":"JAW Gold","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"pone.0316681.ref032","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaad.2017.07.050","article-title":"Socioeconomic and geographic barriers to dermatology care in urban and rural US populations","volume":"78","author":"T Vaidya","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"pone.0316681.ref033","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaad.2023.02.008","article-title":"Improving access to dermatology for underserved regions of South Dakota: A need assessment","volume":"89","author":"J Newton","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"pone.0316681.ref034","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/bjd\/ljad213","article-title":"Use of direct microscopy to diagnose superficial mycoses: a survey of UK dermatology practice","volume":"189","author":"DJ Chandler","year":"2023","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"pone.0316681.ref035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/myc.13549","article-title":"Dermatology mycology diagnostics in Ireland: National deficits identified in 2022 that are relevant internationally","volume":"66","author":"J Powell","year":"2023","journal-title":"Mycoses"},{"issue":"11","key":"pone.0316681.ref036","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/17425255.2011.627854","article-title":"Triazole antifungal agents drugdrug interactions involving hepatic cytochrome P450","volume":"7","author":"PO Gubbins","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"pone.0316681.ref037","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00128071-200001010-00002","article-title":"Onychomycosis: Treatment, quality of life, and economic issues","volume":"1","author":"BE Elewski","year":"2000","journal-title":"Am J Clin Dermatol"},{"issue":"1\u20132","key":"pone.0316681.ref038","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000448056","article-title":"Onychomycosis: Practical Approaches to Minimize Relapse and Recurrence","volume":"2","author":"A Tosti","year":"2016","journal-title":"Skin Appendage Disord"},{"key":"pone.0316681.ref039","unstructured":"European Medicines Agency. Assessment report pursuant to Article 30 of Directive 2001\/83\/EC, as amended: Diflucan and associated names. 2011."},{"issue":"5","key":"pone.0316681.ref040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7547\/21-221","article-title":"Poor Antifungal Coverage for Onychomycosis in a Cross-Sectional Analysis of Medicaid Formularies","volume":"112","author":"JM Falotico","year":"2022","journal-title":"J Am Podiatr Med Assoc"},{"key":"pone.0316681.ref041","article-title":"Patient Characteristics, Diagnostic Testing Utilization, and Antifungal Prescribing Pattern for Onychomycosis in the USA: A Cohort Study Using DataDerm, 2016\u20132022","author":"AK Gupta","year":"2024","journal-title":"Skin Appendage Disord"},{"issue":"1","key":"pone.0316681.ref042","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jaad.2019.01.032","article-title":"Pharmacy costs of medications for the treatment of onychomycosis in the United States","volume":"81","author":"EJ Yang","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"pone.0316681.ref043","unstructured":"Pfizer Canada Inc. Product monograph DIFLUCAN (Fluconazole) [Internet]. 2018. https:\/\/pdf.hres.ca\/dpd_pm\/00045911.PDF"},{"key":"pone.0316681.ref044","unstructured":"Valeant Canada LP. Product monograph - Penlac (Ciclopirox Topical Solution, 8% w\/w) Nail Lacquer, Topical Antifungal Agent. 2012; https:\/\/pdf.hres.ca\/dpd_pm\/00015736.PDF"},{"key":"pone.0316681.ref045","unstructured":"Bausch Health Canada Inc. PRODUCT MONOGRAPH - JUBLIA\u00ae Efinaconazole, Topical Solution, 10% w\/w Topical Antifungal Agent [Internet]. 2020. https:\/\/bauschhealth.ca\/wp-content\/uploads\/pdf\/Jublia PM-E-2020-01-20.pdf"},{"key":"pone.0316681.ref046","unstructured":"Mint Pharmaceuticals Inc. Product monograph MINT-ITRACONAZOLE (Itraconazole) [Internet]. 2018. https:\/\/pdf.hres.ca\/dpd_pm\/00044442.PDF"},{"key":"pone.0316681.ref047","unstructured":"Pfizer Inc. KERYDIN (tavaborole) topical solution, 5% [Internet]. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204427s006lbl.pdf"},{"key":"pone.0316681.ref048","unstructured":"Novartis Pharmaceuticals Canada Inc. Product monograph LAMISIL (Terbinafine) [Internet]. 2023. https:\/\/pdf.hres.ca\/dpd_pm\/00066787.PDF"},{"issue":"1","key":"pone.0316681.ref049","doi-asserted-by":"crossref","DOI":"10.1111\/myc.13660","article-title":"Retrospective analysis of onychomycosis prescribing patterns using the medicare part D prescribers database 2016\u20132020","volume":"67","author":"K Roster","year":"2024","journal-title":"Mycoses"},{"key":"pone.0316681.ref050","first-page":"1","article-title":"Navigating electronic health record accuracy by examination of sex incongruent conditions","author":"L Cai","year":"2024","journal-title":"J Am Med Inform Assoc"},{"issue":"2","key":"pone.0316681.ref051","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/2229-3485.153997","article-title":"Ethical issues in electronic health records: A general overview","volume":"6","author":"FF Ozair","year":"2015","journal-title":"Perspect Clin Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T18:24:09Z","timestamp":1736879049000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316681"}},"subtitle":[],"editor":[{"given":"Felix","family":"Bongomin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0316681","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}